CELLO HEALTH PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - GBX | -.--% |
|
-0.31% | +19.70% |
| Sales 2018 | 166M 211M | Sales 2019 | 167M 212M | Capitalization | 143M 182M |
|---|---|---|---|---|---|
| Net income 2018 | 6M 7.64M | Net income 2019 | - 0 | EV / Sales 2018 | 0.66 x |
| Net cash position 2018 | 6.34M 8.08M | Net Debt 2019 | 3.58M 4.56M | EV / Sales 2019 | 0.88 x |
| P/E ratio 2018 |
18.1
x | P/E ratio 2019 |
-155
x | Employees | - |
| Yield 2018 |
3.47% | Yield 2019 |
1.6% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Rebecca Hyde
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jon Williams
BRD | Director/Board Member | 49 | - |
Cello Health plc, formerly Cello Group plc, is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company provides a range of biotech, diagnostics, devices and other non-healthcare clients. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company's pharmaceutical and healthcare clients. The Cello Signal Division provides market research and direct communications services to the Company's consumer facing clients. The Company delivers its services from office networks in the United Kingdom, the United States and Singapore.
Sector
-
- Stock Market
- Equities
- CLL Stock
